Flag­ship-found­ed Evelo Bio­sciences will dis­solve af­ter find­ing no 'vi­able al­ter­na­tive'

Evelo Bio­sciences, a Flag­ship Pi­o­neer­ing biotech that set out to cre­ate new oral med­i­cines dubbed mon­o­clon­al mi­cro­bials, has de­cid­ed to dis­solve af­ter mul­ti­ple clin­i­cal fail­ures and lay­offs doomed its fate ear­li­er this year.

The board de­ter­mined on Mon­day that a dis­so­lu­tion would be “in the best in­ter­ests of Evelo and its stock­hold­ers,” per a late Tues­day SEC fil­ing out­lin­ing the plan, which in­cludes hir­ing a new ex­ec­u­tive from an ac­count­ing firm fo­cused on dis­tressed busi­ness­es and ex­pe­ri­enced in wind­ing down com­pa­nies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER